Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Neoplasia (New York, N.Y.)|August 10, 2000
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopyP Vajkoczy, M D Menger, B Vollmar, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2001
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertensionL Taraseviciene-Stewart, Y Kasahara, L Alger, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 25, 2000
Inhibition of angiogenesis decreases alveolarization in the developing rat lungM Jakkula, T D Le Cras, S Gebb, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 15, 1998
Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylationK E Lipson, L Pang, L J Huber, et al.
International Journal of Cancer|June 22, 2000
Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARCP Vajkoczy, M D Menger, R Goldbrunner, et al.
Cancer Research|January 19, 1999
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor typesT A Fong, L K Shawver, L Sun, et al.
Cancer Research|August 1, 1996
Flk-1 as a target for tumor growth inhibitionL M Strawn, G McMahon, H App, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1997
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamideL K Shawver, D P Schwartz, E Mann, et al.
Cancer Research|August 17, 2000
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumorsA D Laird, P Vajkoczy, L K Shawver, et al.
Pageof 3